3 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMOPending
To evaluate the efficacy of crovalimab compared to eculizumab
Approved WMOPending
To evaluate the safety and tolerability of crovalimab compared witheculizumab